Table 2.
Infection characteristics of patients with invasive infection due to MRSA with vancomycin MIC of 2 μg/ml from 5 U.S. statesa
| Infection characteristic | n (%) |
|---|---|
| PFGE genotype | |
| USA100 | 104 (76) |
| USA300 | 13 (10) |
| USA500 | 12 (9) |
| Other | 7 (5) |
| Not typed | 2 (1) |
| PAP-AUC determination | |
| hVISA (≥0.90 ratio to strain Mu3) | 21 (15) |
| non-hVISA (≤0.89 ratio to strain Mu3) | 117 (85) |
| Epidemiologic category | |
| Hospital onset (HO) | 42 (30) |
| Healthcare-associated community onset (HACO) | 86 (62) |
| Community associated (CA) | 10 (7) |
| Syndromeb | |
| Bloodstream infection | 115 (83) |
| Bloodstream infection only | 62 (54) |
| Skin and/or soft tissue infection | 24 (17) |
| Pneumonia | 19 (14) |
| Osteomyelitis | 13 (9) |
| Endocarditis | 8 (6) |
| Surgical site infection | 8 (6) |
| Urinary tract infection | 5 (4) |
| Arthritis | 5 (4) |
| Follow-up blood cultures collectedc | 58 (42) |
| Persistent bacteremiad | 32 (55) |
| Persistent fevere | 6 (4) |
| Intensive-care-unit admission after initial culture | 26 (18) |
a
Data from the Active Bacterial Core Surveillance for Invasive MRSA Project (n = 138).
b
Some cases had more than one syndrome.
c
At >24 h after initial culture.
d
Up to 7 days.
e
At least 4 days after first positive culture.